A cohort study showed that high PD-L1 expression (>50% of immunohistochemistry reactivity) in treatment-naïve tumors predicts a poor EGFR-TKI response and prognosis of NSCLC patients with TKI-sensitive mutations [141], suggesting that PD-L1 may contribute to EGFR-TKI resistance in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.